Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FGF23 concentrations measured using "intact" assays similar but not interchangeable.

Literature DB >> 23649347

FGF23 concentrations measured using "intact" assays similar but not interchangeable.

Manish D Sinha¹, Charles Turner, David J Goldsmith.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2013 PMID： 23649347 DOI： 10.1007/s11255-013-0451-x

Source DB: PubMed Journal: Int Urol Nephrol ISSN： 0301-1623 Impact factor: 2.370

× No keyword cloud information.

7 in total

Review 1. Forging forward with 10 burning questions on FGF23 in kidney disease.

Authors: Myles Wolf
Journal: J Am Soc Nephrol Date: 2010-05-27 Impact factor: 10.121

2. FGF23: is it ready for prime time?

Authors: Katherine Wesseling-Perry
Journal: Clin Chem Date: 2011-09-13 Impact factor: 8.327

3. Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5.

Authors: Manish D Sinha; Charles Turner; R N Dalton; Pernille Rasmussen; Simon Waller; Caroline J Booth; David J Goldsmith
Journal: Nephrol Dial Transplant Date: 2012-04-23 Impact factor: 5.992

4. Comparison of two assays for fibroblast growth factor (FGF)-23.

Authors: Nobuaki Ito; Seiji Fukumoto; Yasuhiro Takeuchi; Toshiyuki Yasuda; Yukihiro Hasegawa; Fumi Takemoto; Toshihiro Tajima; Kazushige Dobashi; Yuji Yamazaki; Takeyoshi Yamashita; Toshiro Fujita
Journal: J Bone Miner Metab Date: 2005 Impact factor: 2.626

5. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors:
Journal: Kidney Int Suppl Date: 2009-08 Impact factor: 10.545

6. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.

Authors: Erik A Imel; Munro Peacock; Pisit Pitukcheewanont; Howard J Heller; Leanne M Ward; Dorothy Shulman; Moustapha Kassem; Paula Rackoff; Mark Zimering; Alan Dalkin; Elaine Drobny; Giacomo Colussi; Joseph L Shaker; Elizabeth H Hoogendoorn; Siu L Hui; Michael J Econs
Journal: J Clin Endocrinol Metab Date: 2006-03-21 Impact factor: 5.958

7. Correlation among 25-hydroxy-vitamin D assays.

Authors: N Binkley; D Krueger; D Gemar; M K Drezner
Journal: J Clin Endocrinol Metab Date: 2008-03-04 Impact factor: 5.958

7 in total

5 in total

1. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.

Authors: Manish D Sinha; Charles Turner; Caroline J Booth; Simon Waller; Pernille Rasmussen; David J A Goldsmith; John M Simpson
Journal: Pediatr Nephrol Date: 2015-05-15 Impact factor: 3.714

FGF23 concentrations measured using "intact" assays similar but not interchangeable.

Review 1. Forging forward with 10 burning questions on FGF23 in kidney disease.

2. FGF23: is it ready for prime time?

3. Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5.

4. Comparison of two assays for fibroblast growth factor (FGF)-23.

5. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

6. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.

7. Correlation among 25-hydroxy-vitamin D assays.

1. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.

Review 2. The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.

Review 3. The use of fibroblast growth factor 23 testing in patients with kidney disease.

Review 4. Fibroblast growth factor 23: are we ready to use it in clinical practice?

Review 5. FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.